AI-driven drug response prediction holds great promise for advancing personalized cancer treatment. However, the inherent heterogenity of cancer and high cost of data generation make accurate prediction challenging. In this study, we investigate whether incorporating the pretrained foundation model scGPT can enhance the performance of existing drug response prediction frameworks. Our approach builds on the DeepCDR framework, which encodes drug representations from graph structures and cell representations from multi-omics profiles. We adapt this framework by leveraging scGPT to generate enriched cell representations using its pretrained knowledge to compensate for limited amount of data. We evaluate our modified framework using IC$_{50}$ values on Pearson correlation coefficient (PCC) and a leave-one-drug out validation strategy, comparing it against the original DeepCDR framework and a prior scFoundation-based approach. scGPT not only outperforms previous approaches but also exhibits greater training stability, highlighting the value of leveraging scGPT-derived knowledge in this domain.

Explainability is necessary for many tasks in biomedical research. Recent explainability methods have focused on attention, gradient, and Shapley value. These do not handle data with strong associated prior knowledge and fail to constrain explainability results based on known relationships between predictive features. We propose GraphPINE, a graph neural network (GNN) architecture leveraging domain-specific prior knowledge to initialize node importance optimized during training for drug response prediction. Typically, a manual post-prediction step examines literature (i.e., prior knowledge) to understand returned predictive features. While node importance can be obtained for gradient and attention after prediction, node importance from these methods lacks complementary prior knowledge; GraphPINE seeks to overcome this limitation. GraphPINE differs from other GNN gating methods by utilizing an LSTM-like sequential format. We introduce an importance propagation layer that unifies 1) updates for feature matrix and node importance and 2) uses GNN-based graph propagation of feature values. This initialization and updating mechanism allows for informed feature learning and improved graph representation. We apply GraphPINE to cancer drug response prediction using drug screening and gene data collected for over 5,000 gene nodes included in a gene-gene graph with a drug-target interaction (DTI) graph for initial importance. The gene-gene graph and DTIs were obtained from curated sources and weighted by article count discussing relationships between drugs and genes. GraphPINE achieves a PR-AUC of 0.894 and ROC-AUC of 0.796 across 952 drugs. Code is available at https://anonymous.4open.science/r/GraphPINE-40DE.

Preclinical perturbation screens, where the effects of genetic, chemical, or environmental perturbations are systematically tested on disease models, hold significant promise for machine learning-enhanced drug discovery due to their scale and causal nature. Predictive models can infer perturbation responses for previously untested disease models based on molecular profiles. These in silico labels can expand databases and guide experimental prioritization. However, modelling perturbation-specific effects and generating robust prediction performances across diverse biological contexts remain elusive. We introduce LEAP (Layered Ensemble of Autoencoders and Predictors), a novel ensemble framework to improve robustness and generalization. LEAP leverages multiple DAMAE (Data Augmented Masked Autoencoder) representations and LASSO regressors. By combining diverse gene expression representation models learned from different random initializations, LEAP consistently outperforms state-of-the-art approaches in predicting gene essentiality or drug responses in unseen cell lines, tissues and disease models. Notably, our results show that ensembling representation models, rather than prediction models alone, yields superior predictive performance. Beyond its performance gains, LEAP is computationally efficient, requires minimal hyperparameter tuning and can therefore be readily incorporated into drug discovery pipelines to prioritize promising targets and support biomarker-driven stratification. The code and datasets used in this work are made publicly available.

The accurate prediction of drug responses remains a formidable challenge, particularly at the single-cell level and in clinical treatment contexts. Some studies employ transfer learning techniques to predict drug responses in individual cells and patients, but they require access to target-domain data during training, which is often unavailable or only obtainable in future. In this study, we propose a novel domain generalization framework, termed panCancerDR, to address this challenge. We conceptualize each cancer type as a distinct source domain, with its cell lines serving as domain-specific samples. Our primary objective is to extract domain-invariant features from the expression profiles of cell lines across diverse cancer types, thereby generalize the predictive capacity to out-of-distribution samples. To enhance robustness, we introduce a latent independence projection (LIP) module that encourages the encoder to extract informative yet non-redundant features. Also, we propose an asymmetric adaptive clustering constraint, which clusters drug-sensitive samples into a compact group while drives resistant samples dispersed across separate clusters in the latent space. Our empirical experiments demonstrate that panCancerDR effectively learns task-relevant features from diverse source domains, and achieves accurate predictions of drug response for unseen cancer type during training. Furthermore, when evaluated on single-cell and patient-level prediction tasks, our model-trained solely on in vitro cell line data without access to target-domain information-consistently outperforms and matched current state-of-the-art methods. These findings highlights the potential of our method for real-world clinical applications.

The rise of single-cell sequencing technologies has revolutionized the exploration of drug resistance, revealing the crucial role of cellular heterogeneity in advancing precision medicine. By building computational models from existing single-cell drug response data, we can rapidly annotate cellular responses to drugs in subsequent trials. To this end, we developed scGSDR, a model that integrates two computational pipelines grounded in the knowledge of cellular states and gene signaling pathways, both essential for understanding biological gene semantics. scGSDR enhances predictive performance by incorporating gene semantics and employs an interpretability module to identify key pathways contributing to drug resistance phenotypes. Our extensive validation, which included 16 experiments covering 11 drugs, demonstrates scGSDR's superior predictive accuracy, when trained with either bulk-seq or scRNA-seq data, achieving high AUROC, AUPR, and F1 Scores. The model's application has extended from single-drug predictions to scenarios involving drug combinations. Leveraging pathways of known drug target genes, we found that scGSDR's cell-pathway attention scores are biologically interpretable, which helped us identify other potential drug-related genes. Literature review of top-ranking genes in our predictions such as BCL2, CCND1, the AKT family, and PIK3CA for PLX4720; and ICAM1, VCAM1, NFKB1, NFKBIA, and RAC1 for Paclitaxel confirmed their relevance. In conclusion, scGSDR, by incorporating gene semantics, enhances predictive modeling of cellular responses to diverse drugs, proving invaluable for scenarios involving both single drug and combination therapies and effectively identifying key resistance-related pathways, thus advancing precision medicine and targeted therapy development.

The concept of personalised medicine in cancer therapy is becoming increasingly important. There already exist drugs administered specifically for patients with tumours presenting well-defined mutations. However, the field is still in its infancy, and personalised treatments are far from being standard of care. Personalised medicine is often associated with the utilisation of omics data. Yet, implementation of multi-omics data has proven difficult, due to the variety and scale of the information within the data, as well as the complexity behind the myriad of interactions taking place within the cell. An alternative approach to precision medicine is to employ a function-based profile of the cell. This involves screening a range of drugs against patient derived cells. Here we demonstrate a proof-of-concept, where a collection of drug screens against a highly diverse set of patient-derived cell lines, are leveraged to identify putative treatment options for a 'new patient'. We show that this methodology is highly efficient in ranking the drugs according to their activity towards the target cells. We argue that this approach offers great potential, as activities can be efficiently imputed from various subsets of the drug treated cell lines that do not necessarily originate from the same tissue type.

Drug development is a lengthy process with a high failure rate. Increasingly, machine learning is utilized to facilitate the drug development processes. These models aim to enhance our understanding of drug characteristics, including their activity in biological contexts. However, a major challenge in drug response (DR) prediction is model interpretability as it aids in the validation of findings. This is important in biomedicine, where models need to be understandable in comparison with established knowledge of drug interactions with proteins. drGAT, a graph deep learning model, leverages a heterogeneous graph composed of relationships between proteins, cell lines, and drugs. drGAT is designed with two objectives: DR prediction as a binary sensitivity prediction and elucidation of drug mechanism from attention coefficients. drGAT has demonstrated superior performance over existing models, achieving 78\% accuracy (and precision), and 76\% F1 score for 269 DNA-damaging compounds of the NCI60 drug response dataset. To assess the model's interpretability, we conducted a review of drug-gene co-occurrences in Pubmed abstracts in comparison to the top 5 genes with the highest attention coefficients for each drug. We also examined whether known relationships were retained in the model by inspecting the neighborhoods of topoisomerase-related drugs. For example, our model retained TOP1 as a highly weighted predictive feature for irinotecan and topotecan, in addition to other genes that could potentially be regulators of the drugs. Our method can be used to accurately predict sensitivity to drugs and may be useful in the identification of biomarkers relating to the treatment of cancer patients.

The fields of therapeutic application and drug research and development (R&D) both face substantial challenges, i.e., the therapeutic domain calls for more treatment alternatives, while numerous promising pre-clinical drugs have failed in clinical trials. One of the reasons is the inadequacy of Cross-drug Response Evaluation (CRE) during the late stages of drug R&D. Although in-silico CRE models bring a promising solution, existing methodologies are restricted to early stages of drug R&D, such as target and cell-line levels, offering limited improvement to clinical success rates. Herein, we introduce DeepCRE, a pioneering AI model designed to predict CRE effectively in the late stages of drug R&D. DeepCRE outperforms the existing best models by achieving an average performance improvement of 17.7% in patient-level CRE, and a 5-fold increase in indication-level CRE, facilitating more accurate personalized treatment predictions and better pharmaceutical value assessment for indications, respectively. Furthermore, DeepCRE has identified a set of six drug candidates that show significantly greater effectiveness than a comparator set of two approved drugs in 5/8 colorectal cancer organoids. This demonstrates the capability of DeepCRE to systematically uncover a spectrum of drug candidates with enhanced therapeutic effects, highlighting its potential to transform drug R&D.

The development of single-cell sequencing technology had promoted the generation of a large amount of single-cell transcriptional profiles, providing valuable opportunities to explore drug-resistant cell subpopulations in a tumor. However, the drug sensitivity data in single-cell level is still scarce to date, pressing an urgent and highly challenging task for computational prediction of the drug sensitivity to individual cells. This paper proposed scAdaDrug, a multi-source adaptive weighting model to predict single-cell drug sensitivity. We used an autoencoder to extract domain-invariant features related to drug sensitivity from multiple source domains by exploiting adversarial domain adaptation. Especially, we introduced an adaptive weight generator to produce importance-aware and mutual independent weights, which could adaptively modulate the embedding of each sample in dimension-level for both source and target domains. Extensive experimental results showed that our model achieved state-of-the-art performance in predicting drug sensitivity on sinle-cell datasets, as well as on cell line and patient datasets.

Cancer remains a global challenge due to its growing clinical and economic burden. Its uniquely personal manifestation, which makes treatment difficult, has fuelled the quest for personalized treatment strategies. Thus, genomic profiling is increasingly becoming part of clinical diagnostic panels. Effective use of such panels requires accurate drug response prediction (DRP) models, which are challenging to build due to limited labelled patient data. Previous methods to address this problem have used various forms of transfer learning. However, they do not explicitly model the variable length sequential structure of the list of mutations in such diagnostic panels. Further, they do not utilize auxiliary information (like patient survival) for model training. We address these limitations through a novel transformer based method, which surpasses the performance of state-of-the-art DRP models on benchmark data. We also present the design of a treatment recommendation system (TRS), which is currently deployed at the National University Hospital, Singapore and is being evaluated in a clinical trial.